Adam Greene

Adam Greene is currently listed publicly as a Partner at Braidwell, a life sciences-focused investment firm that says it “build[s] and back[s] companies that transform human health.” Braidwell describes its model as flexible capital and partnership for companies at all stages of development and across public and private markets.

Before Braidwell, Greene was a Partner at Deerfield Management. Third-party profiles of Deerfield list him as having joined the firm in 2010 and as a Partner on the Therapeutics team. Deerfield’s own current site describes the firm as a healthcare investment firm with more than $16 billion in assets under management as of December 2025 and a portfolio of more than 200 private and public healthcare investments.

Prior to Deerfield, Greene spent seventeen years as a sell-side pharmaceutical analyst at firms including RBC Capital Markets, JPMorgan, and First Albany. His research coverage focused on generic drug manufacturers, large-cap pharmaceuticals, and specialty pharmaceuticals. He holds a B.S. in Finance from Lehigh University.

• Braidwell’s stated focus is human health: “We build and back companies that transform human health.”
• Braidwell says it provides “flexible capital and thoughtful partnership” to companies “at all stages of development” and across “public and private markets.”
• Braidwell emphasizes investment research, medical science, biostatistics, commercial analysis, financial structuring, data science, AI, and portfolio engineering as part of its investment process.
• Greene’s prior Deerfield role was on the Therapeutics team, and his earlier sell-side background was concentrated in generic drug manufacturers, large-cap pharmaceuticals, and specialty pharmaceuticals.
• Investor-profile data for Greene under Deerfield lists sector rankings in pharmaceuticals, biotech, health IT, digital health, and health and hospital services at Seed and Series A stages.
• Deerfield’s current investment page says it invests across therapeutics, medical devices, healthcare services, diagnostics, and digital health, and across the capital structure from early-stage startup to mature public or private company.